BOCA RATON, Fla., Jan. 26 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals announced today that Thomas E. Rathjen has been named vice president of investor relations. Mr. Rathjen, a veteran of Wall Street, brings with him over 20 years of experience to Nabi Biopharmaceuticals. Most recently, he served as vice president, investor relations at Genencor International, a Palo Alto-based biotechnology company that develops and delivers innovative products and services for the healthcare and bioproducts markets. Prior to this position, Mr. Rathjen held positions at the New York Stock Exchange (NYSE) and the Nasdaq Stock Market.
At Genencor, Mr. Rathjen was responsible for managing all aspects of its investor relations program, and successfully repositioned the company to expand sell-side analytical support and broaden its institutional investor base. Prior to Genencor, he was vice president at the New York Stock Exchange, where he opened and managed the Big Board's first office outside of New York City and had oversight responsibility for all NYSE-listed companies in 13 western states. Mr. Rathjen was also senior director at the Nasdaq Stock Market where he maintained the relationships of selected NASDAQ 100 companies with a focus on trading, corporate governance and market-related issues.
"Tom brings with him extensive experience in investor relations and securities marketing," stated Thomas H. McLain, chairman, chief executive officer and president, Nabi Biopharmaceuticals. "He is well respected in the investment community and his relationships with many notable analyst firms and investment banks will be instrumental in taking Nabi Biopharmaceuticals' investor relations program to the next level."
Mr. Rathjen attended Santa Clara University's graduate school of business and received his B.A. in Political Science from the University of California, Los Angeles.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. We are focusing on developing products addressing commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology), and nicotine addiction. We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a number of products in various stages of clinical and pre-clinical development. The company also filed Marketing Authorization Applications (MAA) in Europe to market Nabi-HB(R) Intravenous [Hepatitis B Immune Globulin (Human) Intravenous] under the trade name HEBIG(TM) for the prevention of hepatitis B disease in HBV-positive liver transplant patients; and for PhosLo, which is already marketed in the United States. The company's products in development include NicVAX(TM) (Nicotine Conjugate Vaccine), a vaccine to treat nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing hepatitis C virus re-infection in liver transplant patients. For additional information on Nabi Biopharmaceuticals, please visit our website: http://www.nabi.com/ .
First Call Analyst:
FCMN Contact: njohnson@nabi.com
© 2006 PR Newswire
